Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience

2019 ◽  
Vol 125 (2) ◽  
pp. 253-259 ◽  
Author(s):  
Mohamed Saad ◽  
Marco Moschini ◽  
Armando Stabile ◽  
Petr Macek ◽  
Camille Lanz ◽  
...  
Keyword(s):  
Nerve Sparing ◽  
Single Centre ◽  
Oncological Outcomes ◽  
Single Centre Experience ◽  
Prostate Capsule

scholarly journals Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Valentine Frydman ◽  
Ugo Pinar ◽  
Maher Abdessater ◽  
William Akakpo ◽  
Pietro Grande ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Erectile Dysfunction ◽  
Penile Prosthesis ◽  
Perioperative Outcomes ◽  
Single Centre ◽  
Satisfactory Outcome ◽  
Single Centre Experience ◽  
Life Threatening ◽  
Few Data

Abstract Background Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. Results A total of 130 patients received a PP (median age: 62.5 years [IQR: 58–69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5–7]). Median follow-up was 6.3 years [IQR: 4–9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. Conclusions PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.

scholarly journals Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience

2021 ◽  
Author(s):  
E. Sala ◽  
G. Carosi ◽  
G. Del Sindaco ◽  
R. Mungari ◽  
A. Cremaschi ◽  
...  
Keyword(s):  
Median Time ◽  
Pituitary Surgery ◽  
Somatostatin Analogues ◽  
Exclusion Criterion ◽  
Single Centre ◽  
Disease Evolution ◽  
Single Centre Experience ◽  
Pituitary Irradiation

Abstract Purpose A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has been described in some series. Our aim was to update the disease evolution after SAs withdrawal in a cohort of acromegalic patients. Methods We retrospectively evaluated 21 acromegalic patients previously included in a multicentre study (Ronchi et al. 2008), updating data at the last follow-up. We added further 8 patients selected for SAs withdrawal between 2008–2018. Pituitary irradiation represented an exclusion criterion. The withdrawal was suggested after at least 9 months of clinical and hormonal disease control. Clinical and biochemical data prior and after SAs withdrawal were analysed. Results In the whole cohort (29 patients) mean age was 50 ± 14.9 years and 72.4% were females. In 69% pituitary surgery was previously performed. Overall, the median time of treatment before SAs withdrawal was 53 months (IQR = 24–84). At the last follow up in 2019, 23/29 patients (79.3%) had a disease relapse after a median time of 6 months (interquartile range or IQR = 3–12) from the drug suspension, while 6/29 (20.7%) were still on remission after 120 months (IQR = 66–150). IGF-1 levels were significantly lower before withdrawal in patients with persistent remission compared to relapsing ones (IGF-1 SDS: -1.5 ± 0.6 vs -0.11 ± 1, p = 0.01). We did not observe any other difference between patients with and without relapse, including SAs formulation, dosage and treatment duration. Conclusion A successful withdrawal of SAs is possible in a subset of well-controlled acromegalic patients and it challenges the concept that medical therapy is a lifelong requirement.

Long-term Implications of Pacemaker Insertion in Younger Adults: A Single Centre Experience

2021 ◽  
Vol 30 ◽  
pp. S160
Author(s):  
A. Shirwaiker ◽  
J. William ◽  
J. Mariani ◽  
P. Kistler ◽  
H. Patel ◽  
...  
Keyword(s):  
Single Centre ◽  
Younger Adults ◽  
Single Centre Experience ◽  
Pacemaker Insertion

Oncological outcomes of total glossectomy procedure for advanced tongue cancer: a single-centre experience

2021 ◽  
Author(s):  
Hemantkumar Nemade ◽  
Avinash Chaitanya S ◽  
Sravan Kumar ◽  
Anil Kumar A ◽  
T. Subramanyeshwar Rao ◽  
...  
Keyword(s):  
Tongue Cancer ◽  
Single Centre ◽  
Oncological Outcomes ◽  
Single Centre Experience

Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children

2009 ◽  
Vol 21 (12) ◽  
pp. 1413-1418 ◽  
Author(s):  
Jérôme Dumortier ◽  
Carlos Torres Arita ◽  
Christine Rivet ◽  
Catherine LeGall ◽  
Raymonde Bouvier ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Term Treatment ◽  
Single Centre ◽  
Single Centre Experience ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document